S-1/A: AIM ImmunoTech Files Amended Prospectus for $10 Million Unit Offering Amidst Financial Distress and Delisting Concerns

AIM ImmunoTech Inc. is seeking to raise up to $10 million through a unit offering of common stock and warrants to address a negative stockholders' equity and regain compliance with NYSE American listing standards, following a recent reverse stock split and temporary delisting.

Summary

• AIM ImmunoTech Inc. is offering up to 1,052,631 Units, each consisting of one share of common stock (or a Pre-Funded Warrant), one Class E warrant, and one Class F warrant, at an assumed public offering price of $9.50 per Unit, aiming for gross proceeds of approximately $10.0 million.
• The company's common stock was suspended from NYSE American trading on April 7, 2025, moving to OTC Pink under symbol AIMID, but was reinstated to NYSE American under symbol AIM on June 17, 2025, following a 1-for-100 reverse stock split effective June 12, 2025.
• As of March 31, 2025, the company reported approximately negative $3.9 million in stockholders' equity, falling below the NYSE American's minimum requirement of $6.0 million, with a deadline of June 11, 2026, to regain compliance.
• The net proceeds from the offering, estimated at approximately $9.0 million if fully subscribed, are intended for working capital, paying outstanding and future payables, bolstering clinical programs, manufacturing costs, and potentially repaying a recent bridge loan.
• The company has a history of operating losses and expects to incur additional near-term losses, raising substantial doubt about its ability to continue as a going concern.
• Clinical development priorities include Ampligen for pancreatic cancer (Phase 2 enrollment commenced), tumor microenvironment modification with checkpoint inhibitors, antiviral activities, ME/CFS and Post-COVID fatigue, and as a vaccine adjuvant for influenza (including avian influenza) with AstraZeneca's FluMist.
• A recent unsecured bridge loan of $310,000 (net proceeds $250,000) was received from Streeterville Capital LLC on June 30, 2025, due in 120 days, with an early payment discount option.
• The offering is on a 'reasonable best efforts' basis with no minimum amount of securities required to be sold, meaning the company may receive significantly less than the maximum proceeds.
• Investors in this offering will experience immediate and substantial dilution, with an estimated dilution of $7.87 per share based on the assumed public offering price of $9.50 per Unit.
• The company will pay Maxim Group LLC a 7.0% cash transaction fee on gross proceeds and issue placement agent warrants to purchase 5.0% of the Units sold at an exercise price of 110% of the public offering price.
• The offering is expected to terminate on November 30, 2025, unless fully subscribed or terminated earlier at the company's discretion.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including negative stockholders' equity and substantial doubt about its ability to continue as a going concern. The capital raise is critical for survival and compliance, but its 'reasonable best efforts' nature and significant dilution for investors indicate a high-risk, distressed situation. While clinical progress is noted, the financial foundation is extremely weak.

Positives

• Enrollment of patients in the Phase 2 study of Ampligen and Imfinzi for late-stage pancreatic cancer has commenced, following approval from the Erasmus Medical Center Safety Committee.
• The company's shares were reinstated for trading on the NYSE American under the symbol AIM on June 17, 2025, after a temporary suspension and reverse stock split.
• The NYSE American accepted the company's plan to regain compliance with listing standards, providing a deadline of June 11, 2026.
• Engagement with Amarex Clinical Research for a follow-up Investigational New Drug (IND) application for a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist.

Negatives

• The company is not currently in compliance with the NYSE American's stockholders' equity rule, with a negative stockholders' equity of approximately $3.9 million as of March 31, 2025, significantly below the $6.0 million minimum.
• There is substantial doubt about the company's ability to continue as a going concern due to a history of operating losses since inception and expected continued near-term losses.
• The offering is a 'reasonable best efforts' offering with no minimum amount required to be sold, meaning the company may not raise sufficient capital to fund its intended uses or regain NYSE American compliance.
• Investors in this offering will experience immediate and substantial dilution of $7.87 per share based on the assumed public offering price.
• The company has limited cash, cash equivalents, and marketable securities, approximately $2.2 million as of March 31, 2025, indicating a need for significant additional funding.
• There is no established trading market for the Pre-Funded Warrants or the Class E and Class F warrants, limiting their liquidity.

Risks

• The offering is a 'reasonable best efforts' offering with no minimum amount of securities required to be sold, which may result in insufficient capital to execute business plans.
• Investors will experience immediate and substantial dilution in the book value of their investment, as the public offering price is substantially higher than the net tangible book value per share.
• Management will have broad discretion over the use of proceeds, and there is no guarantee that the application of these proceeds will increase investment value.
• A history of operating losses and expected continued losses raise substantial doubt about the company's ability to continue as a going concern.
• Failure to regain compliance with NYSE American listing requirements by June 11, 2026, could lead to delisting, affecting stock price, liquidity, and ability to raise capital.
• The company will require additional financing in the future, which may not be available on acceptable terms or at all, potentially impacting product development and operations.
• Future issuances of securities to raise additional funds or develop strategic relationships could further dilute ownership and negatively impact the common stock trading price.
• The warrants and Pre-Funded Warrants are speculative in nature, and an active trading market for them is not expected to develop, limiting their liquidity.
• Provisions of the warrants could discourage an acquisition of the company by a third party.
• A possible short squeeze due to sudden demand exceeding supply may lead to price volatility in the common stock.
• An active, liquid, and orderly trading market for the common stock may not develop or be sustained, making it difficult for investors to sell shares.
• Extreme fluctuations in the common stock price could occur due to a limited public float and various internal and external factors.
• The offering itself may cause the trading price of the common stock to decrease due to the increased number of shares available.
• If the common stock becomes subject to 'penny stock' rules (price less than $5.00 and not listed on a national exchange), it would become more difficult to trade shares, limiting liquidity.
• In the event of dissolution, holders of securities may lose all or substantial amounts of their investments, as creditors would be paid first.
• Cessation of research or adverse changes in recommendations by securities analysts could cause stock price and trading volume to decline.
• Actions by activist investors, including proxy contests and related litigation, could be costly, time-consuming, disrupt operations, and create perceived uncertainties about the company's future direction.

Future Outlook

The company intends to prioritize clinical work in trials authorized by the FDA or European Medicines Agency (EMA) to support potential future new drug applications (NDAs). Antiviral experimentation is designed to accumulate additional preliminary data supporting Ampligen as a broad-spectrum prophylaxis and early-onset therapeutic. The company believes it does not have adequate funds to meet anticipated operational cash needs and fund current clinical trials and will need to obtain additional funding in the future.

Management Comments

• We are prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation.
• We intend that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (EMA), which trials support a potential future new drug application (NDA).
• Our antiviral experimentation is designed to accumulate additional preliminary data supporting the hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection.
• We believe, based on our current financial condition, that we do not have adequate funds to meet our anticipated operational cash needs and fund current clinical trials.

Industry Context

The company operates in the immuno-pharma sector, focusing on therapeutics for cancers, viral diseases, and immune-deficiency disorders. Its flagship product, Ampligen, is a double-stranded RNA molecule, a class of therapeutics that has seen increasing interest for its potential in oncology and antiviral applications. The pursuit of combination therapies with checkpoint inhibitors (like Imfinzi) for cancer and nasal spray vaccines (like AstraZeneca's FluMist) for influenza aligns with broader industry trends towards synergistic treatments and prophylactic strategies. However, the company's significant financial challenges and 'going concern' doubt contrast sharply with the capital-intensive nature of pharmaceutical R&D, where sustained funding is critical for long-term success and competitive positioning.

Comparison to Industry Standards

• The company's negative stockholders' equity of approximately $3.9 million as of March 31, 2025, and its 'going concern' qualification are significantly below typical financial health benchmarks for publicly traded pharmaceutical companies, which often require substantial capital reserves to fund lengthy and expensive drug development cycles.
• The reliance on a 'reasonable best efforts' offering with no minimum proceeds is a less favorable financing structure compared to firm commitment underwritings common for more financially stable or advanced-stage biotech companies, indicating a higher risk profile for investors.
• While the Phase 2 study for pancreatic cancer with Imfinzi is a positive step, many comparable oncology drug development programs by larger pharmaceutical companies or well-funded biotechs are often supported by significantly larger capital bases and more robust clinical pipelines, reducing their individual project risk.
• The pursuit of Ampligen as a broad-spectrum antiviral and vaccine adjuvant aligns with global health priorities, particularly post-pandemic, but the company's financial constraints may limit its ability to compete effectively with larger players like AstraZeneca (mentioned in the filing) or Moderna/Pfizer, who have vast resources for rapid development and manufacturing.

Corporate Governance

Related Party Transactions

• On June 30, 2025, the company received net proceeds of $250,000 from an unsecured bridge loan of $310,000 from Streeterville Capital LLC, which includes an original issue discount (OID) of $50,000 and Streeterville expenses of $10,000. Repayment is due in 120 days, with an early payment discount if repaid before September 28, 2025.
• Streeterville Capital previously provided $2.5 million in cash in exchange for an unsecured promissory note of $3,301,250 (including OID of $781,250 and $20,000 in fees) that matures in February 2026. Streeterville has agreed to accept payment in stock in lieu of the $250,000 monthly cash payments for a number of months, and has not recently requested cash payments but can do so at its discretion.

Stakeholder Impact

• **Shareholders:** Will experience immediate and substantial dilution from the offering. Existing shareholders face potential further dilution if the company needs to raise more capital or if warrants are exercised. The risk of delisting from NYSE American could severely impact liquidity and share price.
• **Employees:** Continued operations and clinical programs depend on successful capital raise, providing job security. Failure to raise sufficient funds could lead to business limitations or cessation.
• **Customers/Patients:** Continued development of Ampligen for various diseases (cancers, viral diseases, ME/CFS) is contingent on funding, potentially impacting future access to therapies.
• **Creditors (e.g., Streeterville Capital):** The company's ability to repay loans depends on the success of this offering and future financial health. The offering proceeds may be used to repay the Streeterville Bridge Note.
• **Placement Agent (Maxim Group LLC):** Will receive significant fees (7.0% cash) and warrants (5.0% of units sold) if the offering is successful, benefiting directly from the capital raise.

Next Steps

• Complete the current unit offering, expected to be completed not later than one business day following the commencement of sales (after the effective date of the registration statement).
• Deliver all securities issued in connection with the offering delivery versus payment or receipt versus payment upon receipt of investor funds.
• Utilize net proceeds for working capital, paying outstanding and future payables, bolstering clinical programs, manufacturing costs, and exercising the early payment discount on the Streeterville Bridge Note.
• Continue efforts to regain compliance with NYSE American's stockholders' equity rule by June 11, 2026.
• Proceed with the Phase 2 study of Ampligen and Imfinzi for late-stage pancreatic cancer, with patient enrollment commenced.
• Seek collaborative grants from government and industry to defray the cost of the potential avian influenza combination therapy study of Ampligen and AstraZeneca's FluMist.
• Evaluate whether to enter into a privately negotiated agreement with the holder of certain existing outstanding warrants to reduce their exercise price.

Key Dates

Recommendation

The company is in a highly precarious financial position, evidenced by negative stockholders' equity, a 'going concern' qualification from its auditors, and the risk of delisting from the NYSE American. While the offering aims to address these issues, it is a 'reasonable best efforts' offering with no minimum, indicating significant uncertainty in raising the necessary capital. The offering is also highly dilutive to existing shareholders. Given the severe financial distress, the high risk of delisting, and the speculative nature of its drug development programs without a clear path to sustained profitability, the investment carries extreme risk. Existing shareholders should consider selling to mitigate further potential losses, and new investors should avoid due to the significant downside risks and lack of clear financial stability.

Keywords

Immuno-pharma, Ampligen, Rintatolimod, Pancreatic cancer, ME/CFS, Post-COVID condition, Antiviral, Vaccine adjuvant, NYSE American, Delisting risk, Reverse stock split, Public offering, Warrants, Pre-funded warrants, Dilution, Going concern, Capital raise, Biotechnology, Clinical trials